CABALETTA BIO, INC. Payments of Stock Issuance Costs
CABALETTA BIO, INC. (CABA) reported Payments of Stock Issuance Costs of $252.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2025-05-15
- CABALETTA BIO, INC. payments of stock issuance costs for the quarter ending 2024-03-31 was $147.00K.
- CABALETTA BIO, INC. payments of stock issuance costs for the quarter ending 2023-06-30 was $6.29M.
- CABALETTA BIO, INC. payments of stock issuance costs for the quarter ending 2019-12-31 was $0.00.
- CABALETTA BIO, INC. payments of stock issuance costs for the quarter ending 2019-09-30 was $0.00.
- CABALETTA BIO, INC. payments of stock issuance costs for fiscal 2024 was $252.00K, a 97.09% decline from fiscal 2023.
- CABALETTA BIO, INC. payments of stock issuance costs for fiscal 2023 was $8.65M, a 254.68% increase from fiscal 2022.
- CABALETTA BIO, INC. payments of stock issuance costs for fiscal 2022 was $2.44M.
- CABALETTA BIO, INC. payments of stock issuance costs for fiscal 2019 was $1.29M, a 665.09% increase from fiscal 2018.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $252.00K 10-K · filed 2025-03-31 | |||
| 2024-03-31 | $147.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $8.65M 10-K · filed 2025-03-31 | |||
| 2023-06-30 | $6.29M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $2.44M 10-K · filed 2024-03-21 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $1.08M derived: sum of 3 quarters · filed 2021-03-16 | $1.29M 10-K · filed 2021-03-16 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.08M derived: sum of 2 quarters · filed 2020-11-10 | $1.29M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.29M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $216.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $169.00K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |